Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 16, 2025 • 8:01 AM ET

Date/Time Source News Release
05/08/2025 08:05 AM EDT GlobeNewswire NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations
05/07/2025 08:00 AM EDT GlobeNewswire NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
04/14/2025 08:00 AM EDT GlobeNewswire NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition
04/07/2025 08:05 AM EDT GlobeNewswire NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD(TM) 2025)
03/25/2025 08:05 AM EDT GlobeNewswire NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD(TM) 2025)
03/13/2025 08:00 AM EDT GlobeNewswire NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit
03/04/2025 01:00 PM EST GlobeNewswire NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
03/03/2025 08:00 AM EST GlobeNewswire NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
02/21/2025 08:00 AM EST GlobeNewswire NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
02/19/2025 08:00 AM EST GlobeNewswire NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site
Page

Additional News

As of June 16, 2025 • 8:01 AM ET

Date/Time Source News Release
06/16/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, June 16th, 2025
06/16/2025 05:31 AM EDT US Earnings Reports Expected earnings - NKGen Biotech Inc.
06/09/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, June 9th, 2025
06/09/2025 05:31 AM EDT US Earnings Reports Expected earnings - NKGen Biotech Inc.
06/03/2025 06:42 PM EDT KlickAnalytics NKGN - Historical Earnings Price Analysis
06/02/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, June 2nd, 2025
06/02/2025 05:31 AM EDT US Earnings Reports Expected earnings - NKGen Biotech Inc.
05/26/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, May 26th, 2025
05/26/2025 05:31 AM EDT US Earnings Reports Expected earnings - NKGen Biotech Inc.
05/19/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, May 19th, 2025
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.